THE CLOSING INSCRIPTION · THE RECORD
Wolverine Legal Status, FDA 503A Category, and Compounding Access
A carved status register: where BPC-157 and TB-500 stand under FDA compounding rules today, and what is on the calendar — stated as scheduled, never as decided.
Wolverine legal status under FDA compounding rules: where access stands and where it is headed
The Wolverine legal status question is moving. Access to BPC-157 and TB-500 through compounding pharmacies is under active FDA review, and it may expand: the FDA's Pharmacy Compounding Advisory Committee (PCAC) has a meeting scheduled for July 23–24, 2026 at which both peptides are listed as bulk drug substances being considered for inclusion on the 503A Bulks List [3]. That is the forward-leaning fact — and it is a scheduled discussion, not a decision. A PCAC discussion is advisory; it is not a final FDA action, and no outcome should be assumed [3].
The present-tense fact sits underneath that momentum. As of the September 29, 2023 update to the FDA's list of nominated bulk drug substances, both of Wolverine's components are in 503A "Category 2" — substances FDA has identified as potentially presenting significant safety risks [2]. Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1, and FDA has stated it would consider acting against a compounder for compounding with one [1]. In plain terms: compounding-pharmacy access to these peptides is currently restricted, even as the July 2026 review approaches. This page is general information about that regulatory landscape, not medical or legal advice, and not an offer to supply any substance.
Both components are Category 2 — and both are on the July 2026 agenda
There is no component carve-out in the Wolverine blend. Both halves are currently Category 2, and both are under the same scheduled review.
BPC-157 (the FDA evaluated the entries "BPC-157 (free base)" and "BPC-157 acetate") was identified as a bulk drug substance that may present significant safety risks and placed in Category 2 for 503A compounding, effective with the September 29, 2023 list update, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide impurities and active-ingredient characterization [2]. BPC-157 is not an FDA-approved drug [2].
TB-500 — listed by FDA as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — was likewise identified as potentially presenting significant safety risks and placed in Category 2, effective with the same September 29, 2023 update, citing concerns including potential immunogenicity for certain routes and a lack of important safety information [2]. FDA's own list entry establishes the relationship: TB-500 is the LKKTETQ fragment associated with thymosin beta-4 [2]. It is not an FDA-approved drug [2].
Both substances appear on the published agenda of the July 23–24, 2026 PCAC meeting as candidates being considered for inclusion on the 503A Bulks List [3]. That single scheduled review covers both halves of the blend at once. Being discussed by PCAC is a step in evaluation, not a final listing decision [1].
How legally compounded peptide access works
Compounding in the U.S. is governed by two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under stricter oversight [1]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; substances not yet listed are evaluated by FDA through a public nomination process informed by PCAC [1].
The lawful access pathway runs in order. A patient is evaluated by an appropriately licensed prescriber — in person or via a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate [4]. If appropriate and lawful, the prescriber issues a valid, patient-specific prescription. The prescription is then dispensed by a state-licensed 503A compounding pharmacy, or for office and batch use sourced from an FDA-registered 503B outsourcing facility [4]. Telehealth is one front-end channel for the prescriber-evaluation step; it does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription [4].
The ingredient-eligibility caveat is the binding one here. A compounded preparation may lawfully be made only when its active ingredient is permitted under the 503A/503B framework, and ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands [4]. Because both BPC-157 and TB-500 are currently Category 2, that caveat applies to the Wolverine pairing today — which is the practical meaning of the access restriction described above [2].
Access and regulatory questions
The questions below are answered from the audited FDA record. They state present-tense facts and reference the July 2026 PCAC meeting only as a scheduled discussion.
Is Wolverine (BPC-157 + TB-500) legal?
Neither constituent is an FDA-approved drug, and the blend has no approved indication [2]. Both components are currently in FDA 503A Category 2 — identified as potentially presenting significant safety risks — so compounding access is restricted [1][2]. Both are also prohibited by WADA for tested athletes [15]. Legal access, where any exists, runs only through the lawful prescriber-prescription-compounder pathway, subject to the ingredient-eligibility rules [4].
Can you get BPC-157 from a compounding pharmacy?
Currently, BPC-157 is in FDA 503A Category 2 (effective with the September 29, 2023 list update), which is not covered by the enforcement-discretion policy for Category 1 substances, so routine 503A compounding access is restricted [1][2]. BPC-157 is on the July 23–24, 2026 PCAC agenda as a candidate for the 503A Bulks List — a scheduled discussion under active review, not a decision [3].
What is the FDA 503A status of Wolverine?
Both of Wolverine's components are in FDA 503A Category 2 as of the September 29, 2023 list update, identified as potentially presenting significant safety risks and not afforded Category 1 enforcement discretion [1][2]. With no eligible-ingredient status today, the blend has no compliant routine 503A pathway, though both components are under active FDA review at the July 23–24, 2026 PCAC meeting [3].